RID Panel Reversible Immune Disturbance (RID) Biomarker Panel
Complex long term illnesses such as inflammatory bowel disease (IBD) and chronic fatigue syndrome (CFS) affect over two million people in the US alone.
In the majority of cases standard of care therapies effectively relieve symptoms.
Some individuals do not respond to treatment and/or have mysterious combinations of symptoms that do not fit a specific disease category. These symptoms include:
• Neurocognitive impairment
• Multi-joint pain
• Gastrointestinal, visual, pulmonary system disturbances
If these symptoms persist for greater than six months, the root cause may be a reversible immune disturbance.
REVERSIBLE IMMUNE DISTURBANCE was first described by Dr. Richie Shoemaker and colleagues in 2010 as chronic inflammatory response syndrome (CIRS) triggered by ciguatera fish poisoning.
Dr. Shoemaker found that Individuals with chronic ciguatera (i.e. cases that do not resolve within a few weeks) are genetically susceptible to developing chronic inflammation. This chronic refractory illness arising from an immune disturbance can last for decades unless steps are taken to eliminate biotoxin exposures.
It has recently been demonstrated that genetically susceptible individuals exposed to naturally occurring biotoxins (other than ciguatera fish toxins) such as mycotoxins from black mold and chronic Lymes Disease can also develop a chronic potentially reversible immune disturbance.
Immune disturbance can be identified by laboratory testing to reveal abnormalities in the regulatory neuropeptide VIP, and inflammatory response biomarkers C4a and TGF beta.
The RID Panel is designed to provide:
•Assessment of HLA-DR/DQ genetic susceptibility to develop chronic inflammation
•VIP regulatory neuropeptide levels
•Inflammation biomarker results for TGF-beta and C4a
•Fast turn around time